National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Brentuximab vedotin (Adcetris®) is indicated for the treatment of adult patients with CD30+ Hodgkin’s lymphoma at increased risk of relapse or progression following autologous stem cell transplant.

 

NCPE Assessment Process Complete
Rapid review commissioned 30/12/2019
Rapid review completed 29/01/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brentuximab vedotin compared with the current standard of care.